Back to Search
Start Over
Transarterial Radioembolization Treatment of Pancreatic Cancer Patients with Liver-Dominant Metastatic Disease Using Yttrium-90 Glass Microspheres: A Single-Institution Retrospective Study.
- Source :
-
Journal of vascular and interventional radiology : JVIR [J Vasc Interv Radiol] 2020 Jul; Vol. 31 (7), pp. 1060-1068. Date of Electronic Publication: 2020 Jun 10. - Publication Year :
- 2020
-
Abstract
- Purpose: To retrospectively evaluate the safety and efficacy of transarterial radioembolization (TARE) with yttrium-90 ( <superscript>90</superscript> Y)-labeled glass microspheres in pancreatic adenocarcinoma patients with liver-dominant metastatic disease.<br />Materials and Methods: This retrospective, single-center study evaluated 26 patients (12 men and 14 women; mean age, 65.5 ± 11.2 years) with liver-dominant metastatic pancreatic cancer who were treated with TARE from April 2010 to September 2017. All patients received systemic chemotherapy before TARE, and 19 received systemic therapy after embolization. Nineteen patients had extrahepatic disease at the time of TARE. Response to treatment was determined by Response Evaluation Criteria in Solid Tumors at 3 months.<br />Results: Median overall survival (OS) from pancreatic cancer diagnosis was 33.0 months (range, 8.5-87.5 months); median OS from diagnosis of liver metastasis was 21.8 months (range, 2.0-86.2 months); and median OS from TARE treatment was 7.0 months (range, 1.0-84.1 months). Grade 1-2 clinical toxicities were noted in 21 patients (80.8%), and 24 patients (92.3%) had grade 1-2 biochemical toxicities. Four patients (15.4%) had grade 3 clinical toxicities, and 6 patients (23.1%) had grade 3 biochemical toxicities. Imaging was available in 22 patients (84.6%) and demonstrated partial response in 1 patient, stable disease in 9 patients, and progressive disease in 12 patients. Improved hepatic progression-free survival was associated in patients younger than 65 years and in those whose carbohydrate antigen 19-9 level decreased or remained stable after treatment.<br />Conclusions: TARE with <superscript>90</superscript> Y-labeled glass microspheres is safe and led to promising OS in liver-dominant metastatic pancreatic cancer.<br /> (Copyright © 2019 SIR. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Adenocarcinoma diagnostic imaging
Adenocarcinoma mortality
Adenocarcinoma secondary
Aged
Disease Progression
Female
Glass
Humans
Male
Microspheres
Middle Aged
Pancreatic Neoplasms diagnostic imaging
Pancreatic Neoplasms mortality
Progression-Free Survival
Radiopharmaceuticals adverse effects
Retrospective Studies
Time Factors
Yttrium Radioisotopes adverse effects
Adenocarcinoma radiotherapy
Embolization, Therapeutic adverse effects
Embolization, Therapeutic mortality
Pancreatic Neoplasms pathology
Radiopharmaceuticals administration & dosage
Yttrium Radioisotopes administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1535-7732
- Volume :
- 31
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Journal of vascular and interventional radiology : JVIR
- Publication Type :
- Academic Journal
- Accession number :
- 32534978
- Full Text :
- https://doi.org/10.1016/j.jvir.2019.11.037